TipRanks
Advertisement
Advertisement

BOLD Stock Latest News

Boundless Bio Amends Merger Agreement with Serapha Bio
Company AnnouncementsBoundless Bio Amends Merger Agreement with Serapha Bio
1M ago
8K
BOLD
BOLD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
BOLD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
BOLD
Boundless Bio, Serapha Bio to combine in all-stock merger
PremiumThe Fly
Boundless Bio, Serapha Bio to combine in all-stock merger
3M ago
BOLD
Boundless Bio to Merge with Serapha Bio, Restructure Operations
PremiumCompany Announcements
Boundless Bio to Merge with Serapha Bio, Restructure Operations
3M ago
8K
BOLD
Boundless Bio Shareholders Back Directors and Auditor Appointments
PremiumCompany Announcements
Boundless Bio Shareholders Back Directors and Auditor Appointments
3M ago
8K
BOLD
Boundless Bio Halts Early Cancer Trial, Resetting Expectations for BOLD
PremiumCompany AnnouncementsBoundless Bio Halts Early Cancer Trial, Resetting Expectations for BOLD
4M ago
BOLD
Boundless Bio reports Q1 EPS (60c), consensus (56c)
Premium
The Fly
Boundless Bio reports Q1 EPS (60c), consensus (56c)
5M ago
BOLD
Boundless Bio presents preclinical data for BBI-940 therapy at AACR
Premium
The Fly
Boundless Bio presents preclinical data for BBI-940 therapy at AACR
6M ago
BOLD
Boundless Bio Terminates Major Long-Term San Diego Lease
PremiumCompany Announcements
Boundless Bio Terminates Major Long-Term San Diego Lease
6M ago
8K
BOLD
Boundless Bio reports Q4 EPS (58c), consensus (52c)
PremiumThe Fly
Boundless Bio reports Q4 EPS (58c), consensus (52c)
7M ago
BOLD
Boundless Bio sees cash runway into 2H28
PremiumThe Fly
Boundless Bio sees cash runway into 2H28
7M ago
BOLD
Boundless Bio Advances New Breast Cancer Drug BBI-940 Into First-in-Human Trial
PremiumCompany Announcements
Boundless Bio Advances New Breast Cancer Drug BBI-940 Into First-in-Human Trial
8M ago
BOLD
Boundless Bio announces FDA accepted IND application of BBI-940
PremiumThe FlyBoundless Bio announces FDA accepted IND application of BBI-940
8M ago
BOLD
Boundless ceases enrollment of Phase 1/2 Potentiate trial of BBI-355, BBI-825
Premium
The Fly
Boundless ceases enrollment of Phase 1/2 Potentiate trial of BBI-355, BBI-825
8M ago
BOLD
Boundless Bio Terminates Early-Stage BBI-825 Cancer Trial: What Investors Should Know
Premium
Company Announcements
Boundless Bio Terminates Early-Stage BBI-825 Cancer Trial: What Investors Should Know
9M ago
BOLD
Boundless Bio Inc. Reports Q3 2025 Financial Results
PremiumCompany Announcements
Boundless Bio Inc. Reports Q3 2025 Financial Results
11M ago
BOLD
Boundless Bio reports Q3 EPS (62c), consensus (58c)
PremiumThe Fly
Boundless Bio reports Q3 EPS (62c), consensus (58c)
11M ago
BOLD
Boundless Bio sees cash runway into 1H28
PremiumThe Fly
Boundless Bio sees cash runway into 1H28
11M ago
BOLD
Boundless Bio’s Innovative Cancer Study: A Potential Game-Changer?
PremiumCompany Announcements
Boundless Bio’s Innovative Cancer Study: A Potential Game-Changer?
11M ago
BOLD
Innovative Cancer Treatment Approach and Promising Outlook Drive Buy Rating for Boundless Bio Inc.
PremiumRatingsInnovative Cancer Treatment Approach and Promising Outlook Drive Buy Rating for Boundless Bio Inc.
11M ago
BOLD
Premium
Ratings
Hold Rating on Boundless Bio Inc.: Awaiting Clinical Validation of Innovative Therapies
1y ago
BOLD
Boundless Bio price target lowered to $4 from $5 at H.C. Wainwright
Premium
The Fly
Boundless Bio price target lowered to $4 from $5 at H.C. Wainwright
1y ago
BOLD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >